Century Therapeutics, Inc. (IPSC) Tops Q2 EPS by 7c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.38), $0.07 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $800 thousand versus the consensus estimate of $430 thousand.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Movano (MOVE) Misses Q2 EPS by 195c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49